Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0C9IS
|
|||
| Former ID |
DIB014180
|
|||
| Drug Name |
P-9808
|
|||
| Synonyms |
Porphogen; Porphozym; PBGD, HemeBiotech; PBGD, Zymenex; Recombinant porphobilinogen deaminase, HemeBiotech; Recombinant porphobilinogen deaminase, Zymenex
Click to Show/Hide
|
|||
| Indication | Porphyria [ICD-11: 5C58.1; ICD-10: E80.2; ICD-9: 277.1] | Phase 2 | [1] | |
| Company |
Zymenex A/S
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Porphobilinogen deaminase (HMBS) | Target Info | Modulator | [2] |
| BioCyc | Heme biosynthesis | |||
| Tetrapyrrole biosynthesis | ||||
| KEGG Pathway | Porphyrin and chlorophyll metabolism | |||
| Metabolic pathways | ||||
| Panther Pathway | Heme biosynthesis | |||
| Pathwhiz Pathway | Porphyrin Metabolism | |||
| WikiPathways | Heme Biosynthesis | |||
| Metabolism of porphyrins | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00418795) Porphozym in the Treatment of Acute Attacks in AIP. U.S. National Institutes of Health. | |||
| REF 2 | Safety, pharmacokinetics and pharmocodynamics of recombinant human porphobilinogen deaminase in healthy subjects and asymptomatic carriers of the acute intermittent porphyria gene who have increased porphyrin precursor excretion. Clin Pharmacokinet. 2007;46(4):335-49. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.